Sex-specific disruptions in PKCγ signaling in a mouse model of spinocerebellar ataxia type 14
JCI Insight · 22.05.2026 · 11 (10)
DOI: 10.1172/jci.insight.192155 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, online erschienen am 02.04.2026. Verfasst von Sarah A Wolfe und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, UCSD, La Jolla, California, USA. Hauptthemen laut MEDLINE: Protein Kinase C, Spinocerebellar Ataxias. Die Arbeit nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH.
Abstract (Originalsprache)
Spinocerebellar ataxia type 14 (SCA14) is an autosomal dominant neurodegenerative disease caused by mutations in the gene encoding protein kinase C γ (PKCγ), a Ca 2+ - and diacylglycerol-dependent Ser/Thr kinase dominantly expressed in cerebellar Purkinje cells. These mutations impair autoinhibitory constraints to increase the basal activity of the kinase, resulting in deficits in the cerebellum that are not observed upon simple deletion of the gene, and severe ataxia. To better understand the impact of aberrant PKCγ signaling in disease pathology, we developed a knockin murine model of the SCA14 mutation ΔF48 in PKCγ. This fully penetrant mutation is severe in humans and is mechanistically informative, as it has high basal activity but is unresponsive to agonist stimulation. Genetic, behavioral, and molecular testing revealed that ΔF48 PKCγ mice have ataxia-related phenotypes and an altered cerebellar phosphoproteome driven primarily by enhanced Ca 2+ /calmodulin-dependent kinase 2 signaling, effects that were more severe in male mice. Analysis of existing human data revealed that SCA14 has a significantly earlier age of onset for males compared with females. Data from this clinically relevant mutation suggested that enhanced basal activity of PKCγ is sufficient to cause ataxia and that treatment strategies to modulate aberrant PKCγ may be particularly beneficial in males.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, UCSD, La Jolla, California, USA.
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Chemistry and Biochemistry, Biomolecular and Proteomics Mass Spectrometry Facility, UCSD, La Jolla, California, USA.
- Animal Models Core Facility, The Scripps Research Institute, La Jolla, California, USA.
- The UCSD Transgenic Mouse Core, and.
Förderung
- NCI NIH HHS
- NIH
Zitieren
APA
Wolfe, S. A., Ma, Y., Yaron-Barir, T. M., Chang, C., Pilo, C. A., Ghassemian, M., Roberts, A. J., Lee, S. R., Henson, B. A., Jepsen, K., Johnson, J. L., Cantley, L. C., Taylor, S. S., Gorrie, G., & Newton, A. C. (2026). Sex-specific disruptions in PKCγ signaling in a mouse model of spinocerebellar ataxia type 14. JCI Insight, 11(10). https://doi.org/10.1172/jci.insight.192155
Vancouver
Wolfe SA, Ma Y, Yaron-Barir TM, Chang C, Pilo CA, Ghassemian M, et al. Sex-specific disruptions in PKCγ signaling in a mouse model of spinocerebellar ataxia type 14. JCI Insight. 2026;11(10). doi:10.1172/jci.insight.192155
BibTeX
@article{Wolfe2026,
author = {Wolfe, Sarah A and Ma, Yuliang and Yaron-Barir, Tomer M and Chang, Carly and Pilo, Caila A and Ghassemian, Majid and Roberts, Amanda J and Lee, Sang Ryeul and Henson, Benjamin A and Jepsen, Kristen and Johnson, Jared L and Cantley, Lewis C and Taylor, Susan S and Gorrie, George and Newton, Alexandra C},
title = {Sex-specific disruptions in PKCγ signaling in a mouse model of spinocerebellar ataxia type 14},
journal = {JCI Insight},
year = {2026},
volume = {11},
number = {10},
doi = {10.1172/jci.insight.192155}
}
EUVIMED